Eton Pharmaceuticals (NASDAQ:ETON) Price Target Raised to $52.00

Eton Pharmaceuticals (NASDAQ:ETON) had its target price boosted by HC Wainwright from $37.00 to $52.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a buy rating on the stock.

Several other analysts also recently weighed in on ETON. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Thursday, January 22nd. B. Riley Financial raised their price target on Eton Pharmaceuticals from $26.00 to $31.00 and gave the company a “buy” rating in a report on Friday. Zacks Research upgraded shares of Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Wall Street Zen downgraded shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, December 13th. Finally, Craig Hallum increased their target price on shares of Eton Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $39.33.

Eton Pharmaceuticals Price Performance

Shares of NASDAQ:ETON opened at $22.32 on Friday. The firm’s 50 day moving average is $16.72 and its two-hundred day moving average is $17.38. The firm has a market capitalization of $608.89 million, a P/E ratio of -123.99 and a beta of 1.19. The company has a current ratio of 1.57, a quick ratio of 1.17 and a debt-to-equity ratio of 0.83. Eton Pharmaceuticals has a 52 week low of $11.09 and a 52 week high of $23.00.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings data on Thursday, March 19th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.07). Eton Pharmaceuticals had a negative return on equity of 2.60% and a negative net margin of 5.75%.The business had revenue of $21.28 million for the quarter, compared to analyst estimates of $20.58 million. Analysts anticipate that Eton Pharmaceuticals will post -0.14 earnings per share for the current year.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Millennium Management LLC raised its holdings in shares of Eton Pharmaceuticals by 156.3% in the 1st quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock worth $4,620,000 after purchasing an additional 217,042 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Eton Pharmaceuticals by 34.9% during the first quarter. Goldman Sachs Group Inc. now owns 175,220 shares of the company’s stock worth $2,274,000 after buying an additional 45,341 shares in the last quarter. Jane Street Group LLC grew its position in Eton Pharmaceuticals by 49.1% in the first quarter. Jane Street Group LLC now owns 95,919 shares of the company’s stock worth $1,245,000 after buying an additional 31,596 shares during the last quarter. Envestnet Asset Management Inc. grew its position in Eton Pharmaceuticals by 33.1% in the second quarter. Envestnet Asset Management Inc. now owns 23,050 shares of the company’s stock worth $328,000 after buying an additional 5,734 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Eton Pharmaceuticals by 98.8% in the second quarter. Geode Capital Management LLC now owns 592,865 shares of the company’s stock valued at $8,450,000 after buying an additional 294,617 shares in the last quarter. Institutional investors and hedge funds own 27.86% of the company’s stock.

Eton Pharmaceuticals News Roundup

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Several brokerages raised price targets and reiterated buy ratings (HC Wainwright to $52, B. Riley to $31, Craig Hallum to $35), increasing upside expectations and driving bullish investor sentiment. Analyst Upgrades
• Positive Sentiment: Eton acquired U.S. rights to HEMANGEOL, expanding its commercial portfolio in a specialty/rare-disease area and creating a clearer near-term revenue pathway. Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL
• Positive Sentiment: Market commentary highlights a meaningful consensus upside — Zacks notes analysts’ mean targets imply roughly a 49% rally — reinforcing the bullish narrative from upgraded targets. Does Eton Pharmaceuticals Have the Potential to Rally 49.25%?
• Neutral Sentiment: Earnings call and company commentary emphasized record revenue growth and commercial progress, which supports the growth story but did not fully offset margin pressures. Q4 2025 Earnings Call Summary
• Neutral Sentiment: Reported short-interest data for March appears anomalous/flat (0 shares reported and a 0.0 days-to-cover), so it’s unlikely to be a material driver of today’s move. (Data looks unreliable.)
• Negative Sentiment: Q4 results: revenue beat slightly ($21.28M vs. $20.58M est.) but EPS missed ($0.05 vs. $0.12 est.); the company still reports negative net margin and negative ROE, raising profitability concerns. Eton Pharmaceuticals Reports Q4 & Full-Year 2025 Results
• Negative Sentiment: Analyst coverage also flagged the EPS miss in headlines (Zacks: earnings lag estimates), which could cap near-term sentiment until margins improve. Eton Q4 Earnings Lag Estimates

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.